Thomas Thomas T. 4
4 · OPIANT PHARMACEUTICALS, INC. · Filed Sep 23, 2021
Insider Transaction Report
Form 4
Thomas Thomas T.
Director
Transactions
- Exercise/Conversion
Common Stock
2021-09-21$10.00/sh+2,000$20,000→ 10,107 total - Exercise/Conversion
Common Stock
2021-09-22$10.00/sh+1,834$18,340→ 11,110 total - Exercise/Conversion
Stock Option (right to buy)
2021-09-21−2,000→ 1,834 totalExercise: $10.00Exp: 2021-11-03→ Common Stock (2,000 underlying) - Sale
Common Stock
2021-09-21$24.07/sh−60$1,444→ 10,047 total - Sale
Common Stock
2021-09-21$24.12/sh−771$18,597→ 9,276 total - Sale
Common Stock
2021-09-22$25.02/sh−735$18,390→ 10,375 total - Exercise/Conversion
Stock Option (right to buy)
2021-09-22−1,834→ 0 totalExercise: $10.00Exp: 2021-11-03→ Common Stock (1,834 underlying)
Footnotes (7)
- [F1]The shares were sold pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.
- [F2]The shares were sold to cover the $10 exercise price of the vested stock options. The net shares of 25, after selling to cover the exercise price, will be held by the Reporting Person.
- [F3]The shares were sold to cover the $10 exercise price of the vested stock options. The net shares of 1,144, after selling to cover the exercise price, will be held by the Reporting Person.
- [F4]The shares were sold to cover the $10 exercise price of the vested stock options. The net shares of 1,099, after selling to cover the exercise price, will be held by the Reporting Person.
- [F5]This transaction was executed in multiple trades at prices ranging from $24.52 to $25.04. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F6]The option was exercised pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.
- [F7]On November 4, 2016, the reporting person was granted an option to purchase 35,000 shares of Common Stock. The options vest as follows: (i) 11,667 share upon the up listing of the Issuer to The NASDAQ Stock Market (which occurred on August 29, 2017); (ii) 11,667 shares upon the cumulative funding of the Issuer in excess of $5,000,000 by institutional investors, commencing May 5, 2016 (which performance criteria was met on December 13, 2016); and (iii) 11,666 shares upon the first submission of a New Drug Application ("NDA") to the FDA for one of Issuer's products by either the Issuer or an Issuer licensee.